These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 12187502)

  • 1. TTV viral load as a marker for immune reconstitution after initiation of HAART in HIV-infected patients.
    Madsen CD; Eugen-Olsen J; Kirk O; Parner J; Kaae Christensen J; Brasholt MS; Ole Nielsen J; Krogsgaard K
    HIV Clin Trials; 2002; 3(4):287-95. PubMed ID: 12187502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of HAART on hepatitis C, hepatitis G, and TT virus in multiply coinfected HIV-positive patients with haemophilia.
    Takamatsu J; Toyoda H; Fukuda Y; Nakano I; Yokozaki S; Hayashi K; Saito H
    Haemophilia; 2001 Nov; 7(6):575-81. PubMed ID: 11851756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance.
    Fogli M; Torti C; Malacarne F; Fiorentini S; Albani M; Izzo I; Giagulli C; Maggi F; Carosi G; Caruso A
    Clin Dev Immunol; 2012; 2012():829584. PubMed ID: 22474482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in the frequencies of torque teno virus subpopulations during HAART treatment in HIV-1-coinfected patients.
    Devalle S; Rua F; Morgado MG; Niel C
    Arch Virol; 2009; 154(8):1285-91. PubMed ID: 19585076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torque Teno Virus plasma level as novel biomarker of retained immunocompetence in HIV-infected patients.
    Schmidt L; Jensen BO; Walker A; Keitel-Anselmino V; di Cristanziano V; Böhm M; Knops E; Heger E; Kaiser R; de Luca A; Oette M; Häussinger D; Timm J; Fuchs A; Lübke N
    Infection; 2021 Jun; 49(3):501-509. PubMed ID: 33537915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse relationship between the titre of TT virus DNA and the CD4 cell count in patients infected with HIV.
    Shibayama T; Masuda G; Ajisawa A; Takahashi M; Nishizawa T; Tsuda F; Okamoto H
    AIDS; 2001 Mar; 15(5):563-70. PubMed ID: 11316992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of TT virus in HIV-1 exposed but uninfected individuals and in HIV-1 infected patients and its influence on CD4+ lymphocytes and viral load.
    Nasser TF; Brajão de Oliveira K; Reiche EM; Amarante MK; Pelegrinelli Fungaro MH; Watanabe MA
    Microb Pathog; 2009 Jul; 47(1):33-7. PubMed ID: 19409976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of Torque teno virus and SEN virus co-infection with HIV in patients from Southern Iran.
    Pirouzi A; Bahmani M; Feizabadi MM; Afkari R
    Rev Soc Bras Med Trop; 2014; 47(3):275-9. PubMed ID: 25075476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torque Teno Virus Load Is Associated With Centers for Disease Control and Prevention Stage and CD4+ Cell Count in People Living With Human Immunodeficiency Virus but Seems Unrelated to AIDS-Defining Events and Human Pegivirus Load.
    Esser PL; Quintanares GHR; Langhans B; Heger E; Böhm M; Jensen BOLE; Esser S; Lübke N; Fätkenheuer G; Lengauer T; Klein F; Oette M; Rockstroh JK; Boesecke C; Di Cristanziano V; Kaiser R; Pirkl M
    J Infect Dis; 2024 Aug; 230(2):e437-e446. PubMed ID: 38230877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent CMV and EBV DNAemia is significantly correlated with a delay in the response to HAART in treatment-naive HIV type 1-positive patients.
    Panagiotakis SH; Soufla G; Baritaki S; Sourvinos G; Passam A; Zagoreos I; Stavrianeas N; Spandidos DA
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):10-8. PubMed ID: 17263627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China.
    Li X; Ding H; Geng W; Liu J; Jiang Y; Xu J; Zhang Z; Shang H
    BMC Infect Dis; 2019 May; 19(1):373. PubMed ID: 31046702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch.
    Tomasoni LR; Patroni A; Torti C; Paraninfo G; Gargiulo F; Quiros-Roldan E; Uccelli MC; Airò P; Tinelli C; Carosi G; Castelli F;
    HIV Clin Trials; 2003; 4(5):311-23. PubMed ID: 14583847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of hepatitis C virus in HIV coinfected patients under antiretroviral therapy.
    Sede M; Parra M; Manrique JM; Laufer N; Jones LR; Quarleri J
    Infect Genet Evol; 2016 Sep; 43():186-96. PubMed ID: 27234841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV DNA and immune alteration during successful HAART.
    Mamadou D; Yu-Huang Z; Xia C; Bo H; Hua-Ying Z; Yan H; Zi C; Qing L; Li-Wen Z; Mei H; Yun-Hai Y; Demba S; Aldebert D; Souleymane M
    Curr HIV Res; 2013 Jun; 11(4):255-62. PubMed ID: 23822818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.